Navigation Links
Neurocrine Biosciences Reports Third Quarter 2011 Results
Date:10/31/2011

SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2011.

For the third quarter of 2011, the Company reported net income of $31.4 million, or $0.56 per fully diluted share outstanding, compared to net income of $3.3 million, or $0.06 per fully diluted share outstanding, for the same period in 2010. For the nine months ended September 30, 2011, the Company reported a net income of $36.2 million, or $0.64 per fully diluted share outstanding, as compared to a net loss of $10.5 million, or $0.20 loss per basic share outstanding, for the same period last year.

The Company's balance sheet on September 30, 2011 reflected total assets of $149.0 million, including cash, investments and receivables of $140.2 million. The asset balances were bolstered during the third quarter through $30.0 million of milestones recognized under the Abbott collaboration agreement.

"The achievement of the two milestones under the Abbott agreement enables us to achieve our $130 million 2011 year-end cash, investments and receivables target for the Company," said Timothy P. Coughlin, Chief Financial Officer of Neurocrine Biosciences. "With Abbott moving elagolix forward in endometriosis and uterine fibroids, we will look to accelerate our VMAT2 Phase II clinical program, as well as bring some of our pre-clinical drug candidates into the clinic."

Revenues for the third quarter of 2011 were $41.6 million, compared to $14.4 million for the same period in 2010. Revenues for the nine months ended September 30, 2011 were $66.3 million, compared to $19.8 million for the same period in 2010. The increase in revenue in the third quarter 2011 is due to two milestones achieved under the Company's collaboration agreement with Abbott. The Company recognized a $10.0 million milestone which was
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... Wellinton, Florida (PRWEB) , ... September 02, 2015 ... ... has been treated and managed with the use of special anti-vascular endothelial growth ... occurs in many more patients, currently does not have a scientific protocol for ...
(Date:9/2/2015)... 2015 Research and Markets ... PharmaBiotech,s new report "Gene Therapy - Technologies, Markets ... markets for gene therapy are difficult to estimate as ... it is marketed in China ... years 2014-2024. The estimates are based on epidemiology of ...
(Date:9/2/2015)... September 2, 2015 Biovista Inc. ... of the 2015 BeHEARD science challenge, a global competition ... disease researchers, access to the latest life science innovations ... repositioning and pathway analytics capability to support Steven ... in the study of Niemann-Pick Disease Type A (NPA), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... Amarin Corporation plc,(NASDAQ: AMRN ) today announced ... to commence a Phase IIa trial in Age,Associated Memory ... IIa trial will be a randomized, double-blind,placebo-controlled study. The ... randomized to receive 1, 2 or 4 grams of ...
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) President ... 26th Annual Healthcare Conference in San Francisco,California, today, ... Mr.,Hrusovsky will discuss Caliper,s outlook for 2008, and ... 2007., Based on preliminary, unaudited financial data ...
... Hagens Berman Sobol Shapiro LLP,( http://www.hbsslaw.com/cellcyte.htm ) ... of CellCyte (OTC Bulletin Board: CCYG) for ... comes after CellCyte,s shares plunged 55 percent,after ... CEO Gary,Reys, educational and professional credentials., ...
Cached Biology Technology:Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 2Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 3Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 4Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today 2Hagens Berman Sobol Shapiro Investigating CellCyte 2
(Date:9/1/2015)... 1, 2015  Automation and pre-processing are reducing ... screening. This is the first step toward a ... become unintrusive. An assortment of portal scanners, biometric ... investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( http://www.frost.com/nf2b ...
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... PITTSBURGHCarnegie Mellon University,s Philip R. LeDuc will join more ... at the National Academies Keck Futures Initiative on Complexity ... Invited participants will discuss the topic of complexity ... systems and achieving a sustainable future. , "This ...
... love sending and receiving text messages through their cell phones ... But now a new study from the University of North ... to reduce children,s chances of becoming overweight or obese later ... behaviors now. Recent studies show that approximately 19 ...
... More than 4,000 health professionals are expected to attend ... to be held from December 3 7, 2008 ... available on the IOF website at www.iofbonehealth.org ... honoured to announce that HRH Princess Mahajakri Sirindhorn of ...
Cached Biology News:Carnegie Mellon's Philip LeDuc participates in think tank forums 2UNC study: Text messaging may help children fight off obesity 2UNC study: Text messaging may help children fight off obesity 3Less than one month to opening of world’s largest global congress on osteoporosis 2
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Biology Products: